Indeed it consists of two transmembrane domains, a large extracellular domain, and two short intracellular domains that are required for CD36 function after substrate binding (Su and Abumrad, 2009)
Para continuar, ingresa atu cuenta trace-id: 61fc5dbd-ba0b-4d66-85ab-f5178a6f1422 Usamos cookies para mejorar tu experiencia en Mercado Libre
These results are generated using PCA embedding calculated through SpaMTPs GraphPCA functions
For endurance athletes, that shows up as stronger sprint finishes, maintained power through the final miles, and less muscle damage after long sessions
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al